Core Points - Richard Fain, the Chairman of Royal Caribbean Group since 1988, will step down in Q4 2025, transitioning to a Director role [1] - Jason Liberty, the current President and CEO, has been elected to succeed Fain as Chairman and CEO, effective Q4 2025 [1][3] - John Brock has taken on the role of Independent Lead Director, bringing experience from his previous leadership roles [2][4] Company Overview - Royal Caribbean Group is a leader in the vacation industry with a fleet of 67 ships across five brands, serving millions of guests annually [5] - The company operates brands such as Royal Caribbean, Celebrity Cruises, and Silversea, and is expanding its land-based vacation experiences [5] - Royal Caribbean Group also holds a 50% joint venture interest in TUI Cruises, which operates brands like Mein Schiff and Hapag-Lloyd Cruises [5]

LANGHORNE, Pa., May 21, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will participate in the 6th Annual CEO Networking Event hosted by Semco Capital in Chicago on Monday, June 2, 2025 from 1-9 p.m. CT. During the event Mr. Levy will participate in a fires ...

NEXGEL (NXGL) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Valter Pinto - Managing DirectorAdam Levy - CEO, President & DirectorJoseph F. McGuire - CFOEric Ramos - Student Portfolio Manager Conference Call Participants Naz Rahman - AnalystNone - Analyst Operator Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NextGel's First Quarter twenty twenty five Financial Results Conference Call. I will now turn the call over to Walter ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $2,810,000, representing a 121% increase year over year compared to $1,270,000 in Q1 2024 [5][21] - Gross margins normalized to 42.4%, compared to 37% in Q4 2024 and 43.6% in Q3 2024 [5][22] - EBITDA loss narrowed to negative $540,000 from negative $840,000 in the same period last year [6][23] - Net loss for Q1 2025 was $710,000, down from a net loss of $850,000 in Q1 2024 [23] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased by 58% year over year, driven by demand from existing customers and new partnerships [5] - Consumer branded products revenue surged by 189% year over year, significantly boosted by the addition of Silly George [5] - The company expects continued growth in both contract manufacturing and consumer products, with a robust pipeline for 2025 [8][11] Market Data and Key Metrics Changes - The company is seeing increased interest in U.S.-made gels due to potential tariff impacts, which may enhance competitiveness against imported products [19] - There is a growing market for hydrogel applications, particularly in laser hair removal, with significant interest from major companies [42] Company Strategy and Development Direction - The company plans to expand its product lines, including new offerings for MetaGel and Cancoderm, and is transitioning Silly George into a broader beauty brand [12][13] - The partnership with Stata is progressing well, with plans for additional product launches in 2025 and 2026 [14] - The company is strategically managing cash and R&D to ensure high ROI while pursuing growth opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about achieving $13,000,000 in revenue and cash flow positivity in 2025 despite external challenges [20] - The company is monitoring tariff situations closely and is prepared to adjust manufacturing strategies if necessary [16][19] - Management expressed confidence in the growth potential of their products and the overall market, despite uncertainties in the broader economic environment [60] Other Important Information - The company has a cash balance of approximately $1,190,000 as of March 31, 2025 [23] - The company has 7,654,537 shares of common stock outstanding as of May 13, 2025 [23] Q&A Session Summary Question: How much revenue was expected from AbbVie, and does the delay affect guidance? - Management indicated that not much revenue was baked in from AbbVie, so the delay should not significantly impact the $13,000,000 projection [25][26] Question: Can you provide details on the product launch with Stata? - The first product is Histosol, a digestive enzyme, with plans for additional digestive enzymes in the future [30] Question: Is there a seasonal improvement expected for Silly George? - Management expects seasonal growth, especially with new product launches planned for Q3 and Q4 [61][62] Question: Will transitioning manufacturing to Texas impact other business lines? - The company has built a new clean room with enough capacity to accommodate potential shifts in manufacturing [35][36] Question: Will the company survive on current cash reserves until EBITDA positive? - Management believes they can manage with current cash reserves until reaching EBITDA positivity [66]

First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its first quarter 2025 financial results for the ...

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2025, after the market close on May 13, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 p ...

Core Points - Royal Caribbean Group declared a quarterly dividend of $0.75 per common share, payable on July 3, 2025, to shareholders of record as of June 4, 2025 [1] Company Overview - Royal Caribbean Group is a leader in the vacation industry with a global fleet of 67 ships across five brands, serving millions of guests annually [2] - The company operates brands including Royal Caribbean, Celebrity Cruises, and Silversea, and is expanding its land-based vacation experiences [2] - Royal Caribbean Group holds a 50% joint venture interest in TUI Cruises, which operates German brands Mein Schiff and Hapag-Lloyd Cruises [2] - The company is known for its history of innovation and commitment to delivering exciting new products and guest experiences in leisure travel [2]

NEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Conference Call March 24, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Joe McGuire - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good afternoon. I will be your conference operator today. At this time, I'd like to welcome everyone to NEXGEL's Fourth Quarter and Full Year 2024 Earnings Conference Call. I will now turn the call over ...